Victoria Rai
About
Research
Publications
2026
Polycystin-1 C-terminal tail suppresses cystic phenotype in autosomal dominant polycystic kidney disease in a Pkd genotype-independent manner
Rai V, Onuchic L, Caplan M. Polycystin-1 C-terminal tail suppresses cystic phenotype in autosomal dominant polycystic kidney disease in a Pkd genotype-independent manner. Physiology 2026, 41: 2297786. DOI: 10.1152/physiol.2026.41.s1.2297786.Peer-Reviewed Original ResearchBulk RNA-seqPatterns of gene expressionRNA-seqCystic phenotypeAutosomal dominant polycystic kidney diseasePolycystin-1Polycystin-1 C-terminal tailGene expressionDominant polycystic kidney diseaseC-terminal tailLoss of Pkd2Mouse models of autosomal dominant polycystic kidney diseasePolycystic kidney diseaseModel of autosomal dominant polycystic kidney diseaseGenotype-independent mannerPKD2 lossDisease suppression mechanismsDisease-causing genotypesTGF-beta signalingOrthologous mouse modelMouse modelCystic diseaseWeeks of ageCystic indexPKD1Su1671 TIME TO FLIP THE SCRIPT: IT’S NOT WHO NEEDS ADVANCED THERAPY FOR INFLAMMATORY BOWEL DISEASE, IT’S IDENTIFYING THOSE WHO DO NOT
Mecsas-Faxon B, Cheifetz A, Barnes E, Rai V, Devlin S, Gecse K, Irving P, Raffals L, Ullman T, Velayos F, Baidoo L, Melmed G, Siegel C. Su1671 TIME TO FLIP THE SCRIPT: IT’S NOT WHO NEEDS ADVANCED THERAPY FOR INFLAMMATORY BOWEL DISEASE, IT’S IDENTIFYING THOSE WHO DO NOT. Gastrointestinal Endoscopy 2026, 103: s-1131. DOI: 10.1016/s0016-5107(26)02809-9.Peer-Reviewed Original ResearchSu1671 TIME TO FLIP THE SCRIPT: IT’S NOT WHO NEEDS ADVANCED THERAPY FOR INFLAMMATORY BOWEL DISEASE, IT’S IDENTIFYING THOSE WHO DO NOT
Mecsas-Faxon B, Cheifetz A, Barnes E, Rai V, Devlin S, Gecse K, Irving P, Raffals L, Ullman T, Velayos F, Baidoo L, Melmed G, Siegel C. Su1671 TIME TO FLIP THE SCRIPT: IT’S NOT WHO NEEDS ADVANCED THERAPY FOR INFLAMMATORY BOWEL DISEASE, IT’S IDENTIFYING THOSE WHO DO NOT. Gastroenterology 2026, 170: s-1131. DOI: 10.1016/s0016-5085(26)02878-7.Peer-Reviewed Original Research
2024
Patients with ulcerative colitis who have normalized histology are clinically stable after de-escalation of therapy
Akiyama S, St-Pierre J, Traboulsi C, Silfen A, Rai V, Rodriguez T, Erondu A, Steinberg J, Shaffer S, Christensen B, Rubin D. Patients with ulcerative colitis who have normalized histology are clinically stable after de-escalation of therapy. Npj Gut And Liver 2024, 1: 5. DOI: 10.1038/s44355-024-00005-9.Peer-Reviewed Original ResearchHistologic normalizationUlcerative colitisDe-EscalationUC patientsDe-escalation of therapyTherapeutic de-escalationMedian Follow-UpDe-escalation groupProportion of patientsStudy assessed outcomesHistological recurrenceRecurrence rateSingle-centerClinical stabilityTherapeutic changeRemission outcomesFollow-upTherapyPatientsImmunomodulationAminosalicylatesWithdrawalColitisMonthsOutcomesWhen Perfect Is the Enemy of Good: Results of a RAND Appropriateness Panel on Treat to Target in Asymptomatic Inflammatory Bowel Disease
Systrom H, Rai V, Singh S, Baidoo L, Cheifetz A, Devlin S, Gecse K, Irving P, Kaplan G, Kozuch P, Ullman T, Sparrow M, Melmed G, Siegel C. When Perfect Is the Enemy of Good: Results of a RAND Appropriateness Panel on Treat to Target in Asymptomatic Inflammatory Bowel Disease. The American Journal Of Gastroenterology 2024, 120: 420-430. PMID: 39008539, DOI: 10.14309/ajg.0000000000002964.Peer-Reviewed Original ResearchConceptsInflammatory bowel diseaseAsymptomatic patientsChanging therapyStable diseaseEndoscopic remissionEndoscopic activityBowel diseaseAsymptomatic inflammatory bowel diseaseRAND/University of California Los Angeles Appropriateness MethodTreat-to-target strategyActive endoscopic diseaseUlcerative colitis patientsCrohn's disease patientsLos Angeles Appropriateness MethodExtensive diseaseDisease extentPatient ageAphthous ulcersRandomized studyEndoscopic diseaseClinical decision-makingColitis patientsAdvanced therapiesTreatment adjustmentAnonymous surveyA Comparative Analysis of Clinical Symptoms and Modified Pouchitis Disease Activity Index Among Endoscopic Phenotypes of the J Pouch in Patients With Inflammatory Bowel Disease
Akiyama S, Cohen N, Ollech J, Traboulsi C, Rodriguez T, Rai V, Glick L, Yi Y, Runde J, Cohen R, Skowron K, Hurst R, Umanskiy K, Shogan B, Hyman N, Rubin M, Dalal S, Sakuraba A, Pekow J, Chang E, Rubin D. A Comparative Analysis of Clinical Symptoms and Modified Pouchitis Disease Activity Index Among Endoscopic Phenotypes of the J Pouch in Patients With Inflammatory Bowel Disease. Crohn's & Colitis 360 2024, 6: otae045. PMID: 39347443, PMCID: PMC11438232, DOI: 10.1093/crocol/otae045.Peer-Reviewed Original ResearchModified pouchitis disease activity indexPouchitis Disease Activity IndexInflammatory bowel diseasePouch-related fistulasDisease activity indexEndoscopic phenotypesComparative analysis of clinical symptomsInflammatory phenotypeClinical symptomsFocal inflammationAfferent limbComplete-case analysisBowel diseaseAnalysis of clinical symptomsActivity indexInflammatory bowel disease patientsAssess symptomsComplete-caseIncomplete emptyingPouch bodyNormal pouchEndoscopic findingsDiagnosing pouchitisDiffuse inflammationPerianal symptomsEndoscopic Normalization and Transition of J-Pouch Phenotypes Over Time in Patients With Inflammatory Bowel Disease
Akiyama S, Ollech J, Cohen N, Traboulsi C, Rai V, Glick L, Yi Y, Runde J, Cohen R, Olortegui K, Hurst R, Umanskiy K, Shogan B, Hyman N, Rubin M, Dalal S, Sakuraba A, Pekow J, Chang E, Rubin D. Endoscopic Normalization and Transition of J-Pouch Phenotypes Over Time in Patients With Inflammatory Bowel Disease. Inflammatory Bowel Diseases 2024, 31: 63-71. PMID: 38916136, PMCID: PMC11700886, DOI: 10.1093/ibd/izae106.Peer-Reviewed Original ResearchPouch-related fistulasInflammatory bowel diseaseNormal pouchDiffuse inflammationFocal inflammationAfferent limbBowel diseaseAssociated with favorable outcomesIleal pouch-anal anastomosisPouch-anal anastomosisPouch lossEndoscopic phenotypesIleostomy takedownFavorable outcomePouch inflammationPouch excisionPouch phenotypesPrimary phenotypeFistulaEndoscopic classificationInflammationPatientsPouch bodyCuffitisPhenotypic transitionRecommendations for Broadening Eligibility Criteria in Inflammatory Bowel Disease Clinical Trials
Siegel C, Rai V, Outtier A, Vermeire S, Law C, Sands B, Abdulhamid A, Gearry R, McGuire J, Lindsay J, Panaccione R, Schweistein H, Dotan I, Scarallo L, Griffiths A, Dubinsky M. Recommendations for Broadening Eligibility Criteria in Inflammatory Bowel Disease Clinical Trials. Journal Of Crohn's And Colitis 2024, 18: jjae097. PMID: 38908002, DOI: 10.1093/ecco-jcc/jjae097.Peer-Reviewed Original ResearchTrial recruitmentClinical trial eligibilityTrial eligibilityInflammatory bowel disease specialistsInflammatory bowel diseaseRAND/UCLA Appropriateness MethodClinical trial recruitmentRepresentative patient populationIBD specialistsEligibility criteriaAppropriate methodsEligibilityAnonymous votingPatient populationPrior medicationsComplicated disease phenotypeBaseline studyRecommendationsInternational groupLiterature reviewSpecialistsInflammatory bowel disease clinical trialsBowel diseaseColonoscopyRAND/UCLA
2023
The C-terminal tail of polycystin-1 suppresses cystic disease in a mitochondrial enzyme-dependent fashion
Onuchic L, Padovano V, Schena G, Rajendran V, Dong K, Shi X, Pandya R, Rai V, Gresko N, Ahmed O, Lam T, Wang W, Shen H, Somlo S, Caplan M. The C-terminal tail of polycystin-1 suppresses cystic disease in a mitochondrial enzyme-dependent fashion. Nature Communications 2023, 14: 1790. PMID: 36997516, PMCID: PMC10063565, DOI: 10.1038/s41467-023-37449-1.Peer-Reviewed Original ResearchConceptsPolycystin-1Nicotinamide nucleotide transhydrogenaseTerminal tailCystic phenotypeAutosomal dominant polycystic kidney diseaseCyst cell proliferationC-terminal domainAmino acid residuesLethal monogenic disorderC-terminal cleavageNucleotide transhydrogenaseAcid residuesMitochondrial functionTransgenic expressionPKD1 geneRedox stateShort fragmentsCell proliferationMonogenic disordersDominant polycystic kidney diseasePolycystic kidney diseaseGene therapy strategiesProteinPhenotypeFragments
2022
Recommendations on the Appropriate Management of Steroids and Discharge Planning During and After Hospital Admission for Moderate-Severe Ulcerative Colitis: Results of a RAND Appropriateness Panel
Dulai P, Rai V, Raffals L, Lukin D, Hudesman D, Kochhar G, Damas O, Sauk J, Levy A, Sofia M, Tuskey A, Deepak P, Yarur A, Afzali A, Ananthakrishnan A, Cross R, Hanauer S, Siegel C. Recommendations on the Appropriate Management of Steroids and Discharge Planning During and After Hospital Admission for Moderate-Severe Ulcerative Colitis: Results of a RAND Appropriateness Panel. The American Journal Of Gastroenterology 2022, 117: 1288-1295. PMID: 35416799, PMCID: PMC9437635, DOI: 10.14309/ajg.0000000000001775.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsModerate-severe flaresUlcerative colitisAntitumor necrosis factor therapyModerate-severe ulcerative colitisNecrosis factor therapyRAND appropriateness panelMethylprednisolone 40Naive patientsPostdischarge managementSteroid dosingStool frequencyRectal bleedingTherapy initiationAdverse eventsFactor therapyInpatient managementPostdischarge careHospital admissionLower endoscopyDischarge planningLower riskPatientsDischarge criteriaAppropriate managementHigh doses